DOXYCYCLINE HYCLATE (doxycycline) by Gland Pharma is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. Approved for infections caused by the following gram-negative microorganisms, infections caused by the following gram-positive microorganisms, 74 percent of enterococcus faecalis have been found to be resistant to tetracycline drugs and 11 more indications. First approved in 2023.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Following a single 100 mg dose administered in a…
Worked on DOXYCYCLINE HYCLATE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Doxycycline vs. Macrolide for MRMP (DOMINO)
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
A Study of Doxycycline to Treat Chlamydial Infection
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo